News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
268,191 Results
Type
Article (14251)
Company Profile (281)
Press Release (253659)
Multimedia
Podcasts (48)
Webinars (7)
Section
Business (79539)
Career Advice (152)
Deals (13231)
Drug Delivery (35)
Drug Development (50462)
Employer Resources (31)
FDA (5724)
Job Trends (5133)
News (144444)
Policy (10032)
Tag
Academia (915)
Accelerated approval (2)
Adcomms (12)
Allergies (52)
Alliances (21677)
ALS (64)
Alzheimer's disease (848)
Antibody-drug conjugate (ADC) (100)
Approvals (5752)
Artificial intelligence (124)
Autoimmune disease (18)
Automation (5)
Bankruptcy (105)
Best Places to Work (4559)
BIOSECURE Act (6)
Biosimilars (43)
Biotechnology (232)
Bladder cancer (59)
Brain cancer (20)
Breast cancer (155)
Cancer (1485)
Cardiovascular disease (117)
Career advice (133)
Career pathing (2)
CAR-T (118)
Cell therapy (332)
Cervical cancer (8)
Clinical research (41093)
Collaboration (542)
Compensation (263)
Complete response letters (13)
COVID-19 (1034)
CRISPR (42)
C-suite (165)
Cystic fibrosis (76)
Data (1531)
Denatured (11)
Depression (31)
Diabetes (139)
Diagnostics (1300)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (85)
Drug pricing (28)
Drug shortages (3)
Duchenne muscular dystrophy (90)
Earnings (29858)
Editorial (18)
Employer branding (4)
Employer resources (29)
Events (48626)
Executive appointments (464)
FDA (6432)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (498)
Gene editing (97)
Generative AI (10)
Gene therapy (254)
GLP-1 (366)
Government (1080)
Grass and pollen (2)
Guidances (27)
Healthcare (6594)
Huntington's disease (22)
IgA nephropathy (25)
Immunology and inflammation (92)
Indications (20)
Infectious disease (1099)
Inflammatory bowel disease (115)
Inflation Reduction Act (8)
Influenza (19)
Intellectual property (67)
Interviews (17)
IPO (7274)
IRA (11)
Job creations (861)
Job search strategy (127)
Kidney cancer (7)
Labor market (5)
Layoffs (209)
Leadership (3)
Legal (1386)
Liver cancer (33)
Lung cancer (205)
Lymphoma (102)
Machine learning (3)
Management (7)
Manufacturing (140)
MASH (54)
Medical device (2600)
Medtech (2601)
Mergers & acquisitions (6288)
Metabolic disorders (391)
Multiple sclerosis (53)
NASH (13)
Neurodegenerative disease (68)
Neuropsychiatric disorders (25)
Neuroscience (1260)
NextGen: Class of 2025 (2017)
Non-profit (852)
Now hiring (21)
Obesity (194)
Opinion (102)
Ovarian cancer (63)
Pain (44)
Pancreatic cancer (56)
Parkinson's disease (121)
Partnered (8)
Patents (130)
Patient recruitment (79)
Peanut (35)
People (25658)
Pharmaceutical (47)
Pharmacy benefit managers (5)
Phase I (14518)
Phase II (19113)
Phase III (12082)
Pipeline (818)
Policy (45)
Postmarket research (852)
Preclinical (6141)
Press Release (30)
Prostate cancer (62)
Psychedelics (35)
Radiopharmaceuticals (213)
Rare diseases (292)
Real estate (1419)
Recruiting (12)
Regulatory (8648)
Reports (15)
Research institute (938)
Resumes & cover letters (17)
Rett syndrome (4)
RNA editing (5)
RSV (10)
Schizophrenia (61)
Series A (98)
Series B (63)
Service/supplier (1)
Sickle cell disease (40)
Special edition (11)
Spinal muscular atrophy (117)
Sponsored (12)
Startups (1975)
State (1)
Stomach cancer (4)
Supply chain (23)
Tariffs (9)
The Weekly (36)
Vaccines (214)
Venture capitalists (32)
Weight loss (110)
Women's health (15)
Worklife (2)
Date
Today (114)
Last 7 days (541)
Last 30 days (1516)
Last 365 days (19539)
2025 (6349)
2024 (20552)
2023 (22415)
2022 (26822)
2021 (27805)
2020 (23356)
2019 (16224)
2018 (11739)
2017 (13745)
2016 (11840)
2015 (14350)
2014 (10393)
2013 (7486)
2012 (7536)
2011 (7617)
2010 (7433)
Location
Africa (148)
Alabama (42)
Alaska (2)
Arizona (53)
Arkansas (5)
Asia (17316)
Australia (2935)
California (3883)
Canada (1143)
China (361)
Colorado (149)
Connecticut (152)
Delaware (103)
Europe (37254)
Florida (468)
Georgia (117)
Idaho (16)
Illinois (233)
India (10)
Indiana (92)
Iowa (2)
Japan (75)
Kansas (62)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (478)
Massachusetts (3094)
Michigan (70)
Minnesota (145)
Mississippi (1)
Missouri (24)
Montana (14)
Nebraska (4)
Nevada (17)
New Hampshire (14)
New Jersey (971)
New Mexico (12)
New York (1050)
North Carolina (556)
North Dakota (5)
Northern California (1714)
Ohio (112)
Oklahoma (9)
Oregon (21)
Pennsylvania (743)
Puerto Rico (6)
Rhode Island (19)
South America (208)
South Carolina (4)
Southern California (1496)
Tennessee (25)
Texas (450)
United States (13327)
Utah (53)
Virginia (79)
Washington D.C. (30)
Washington State (352)
Wisconsin (15)
268,191 Results for "genecentric therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
GeneCentric Therapeutics Launches EXpressCT Liquid Biopsy Platform
October 28, 2024
·
3 min read
Bio NC
GeneCentric Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting
GeneCentric Therapeutics today announced upcoming presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, Illinois from May 31st to June 4th.
May 20, 2024
·
2 min read
Bio NC
GeneCentric Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2024
GeneCentric Therapeutics today announced upcoming presentations at the American Association for Cancer Research Annual Meeting 2024 being held in San Diego, California from April 5-10.
April 1, 2024
·
2 min read
News
GeneCentric Therapeutics Announces Publication of Clinicogenomic Results from GARNER Study in High-Risk Non-Muscle Invasive Bladder Cancer
October 1, 2024
·
3 min read
Business
GeneCentric Therapeutics Appoints Prasanth Reddy and Don Hardison to the Board of Directors as the Company Advances Its Oncology Diagnostics Pipeline
GeneCentric Therapeutics today announced the appointment of Prasanth Reddy, MD, MPH, FACP, and Don Hardison as independent directors of its Board of Directors.
November 14, 2023
·
2 min read
Bio NC
GeneCentric Therapeutics Announces Upcoming Presentations at the American Society of Clinical Oncology Genitourinary Cancers Symposium and Precision Medicine World Conference
GeneCentric Therapeutics today announced upcoming presentations at the Precision Medicine World Conference (PMWC) in Santa Clara, California from January 24-26 and the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), which will be held January 25-27 in San Francisco, California.
January 22, 2024
·
3 min read
Bio NC
GeneCentric Therapeutics Announces Commercial Availability of PurIST℠ Test for Pancreatic Cancer
GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today that its PurIST℠ test is now commercially available through Tempus for clinical use.
May 31, 2023
·
3 min read
Business
GeneCentric Therapeutics Appoints Brian Kelly as SVP Business Development
GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, today announced the appointment of Brian Kelly as Senior Vice President of Business Development.
April 12, 2023
·
2 min read
Business
GeneCentric Therapeutics Announces Publication of New Results Showing Clinical Benefit of RNA-based Antifolate Predictive Response Signature (AF-PRS) to Guide Lung Cancer Treatment Selection
GeneCentric Therapeutics announced today the publication of initial results from the ongoing Piedmont study using real-world data in lung cancer to develop its novel RNA-based Antifolate Predictive Response Signature (AF-PRS), which is being co-developed as a clinical diagnostic test with Labcorp.
July 20, 2023
·
4 min read
Bio NC
GeneCentric Therapeutics Initiates the Alamance Study – A Real-World Investigation of Bladder Cancer Patients Treated with FGFR Inhibitors and Other Standards of Care
GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today the initiation of its Alamance study, a multi-center bladder cancer study conducted in collaboration with investigators at Memorial Sloan Kettering Cancer Center and the University of Wisconsin – Madison Carbone Cancer Center.
May 16, 2023
·
3 min read
1 of 26,820
Next
